MEN2312 for Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the trial involves a new drug, it's possible that some medications might need to be adjusted. Please consult with the trial coordinators for specific guidance.
Is the drug MEN2312 a promising treatment for breast cancer?
What is the purpose of this trial?
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Eligibility Criteria
This trial is for adults with advanced breast cancer. Specific details about eligibility criteria are not provided, but typically participants would need to have a certain stage of cancer and meet health requirements set by the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive MEN2312 as monotherapy or in combination with elacestrant
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- MEN2312
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stemline Therapeutics, Inc.
Lead Sponsor
Stemline Therapeutics, Inc.
Lead Sponsor